NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE Drug Patent Profile

Which patents cover Norepinephrine Bitartrate In 0.9% Sodium Chloride, and what generic alternatives are available?

Norepinephrine Bitartrate In 0.9% Sodium Chloride is a drug marketed by Inforlife and Long Grove Pharms and is included in two NDAs. There are eleven patents protecting this drug.

This drug has forty-nine patent family members in forty countries.

The generic ingredient in NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE is norepinephrine bitartrate. There are five drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norepinephrine Bitartrate In 0.9% Sodium Chloride

A generic version of NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE was approved as norepinephrine bitartrate by MEITHEAL on March 3^rd, 2003.

Summary for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

International Patents:	49
US Patents:	11
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Clinical Trials:	12
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
DailyMed Link:	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE at DailyMed

Recent Clinical Trials for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Visarat Palitnonkiat	PHASE1
Siriraj Hospital	PHASE1
Hassan II University	PHASE4

See all NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE clinical trials

Pharmacology for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

Drug Class

Catecholamine

US Patents and Regulatory Information for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE is protected by eleven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-003	Oct 6, 2022		RX	Yes	Yes	10,568,850		Y
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-003	Oct 6, 2022		RX	Yes	Yes	12,245,996		Y
Inforlife	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	215700-001	Sep 15, 2022		RX	Yes	Yes	RE49422		Y
Long Grove Pharms	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	norepinephrine bitartrate	SOLUTION;INTRAVENOUS	214628-002	Oct 6, 2022		RX	Yes	Yes	10,420,735		Y

International Patents for NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

See the table below for patents covering NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Costa Rica	20160420	PROCESO PARA PRODUCIR UNA SOLUCION INYECTABLE DE NORADRENALINA DE BAJA CONCENTRACION, ESTABLE
Moldova, Republic of	4628
Eurasian Patent Organization	201691734	СПОСОБ ПОЛУЧЕНИЯ СТАБИЛЬНОГО РАСТВОРА ДЛЯ ИНЪЕКЦИЙ С НИЗКОЙ КОНЦЕНТРАЦИЕЙ НОРАДРЕНАЛИНА
Ecuador	SP16065957	PROCESO PARA PRODUCIR UNA SOLUCIÓN INYECTABLE DE NORADRENALINA DE BAJA CONCENTRACIÓN, ESTABLE

Market Dynamics and Financial Trajectory for Norepinephrine Bitartrate in 0.9% Sodium Chloride

Last updated: November 24, 2025

Introduction

Norepinephrine bitartrate in 0.9% sodium chloride solution, commonly marketed as Levophed, remains a cornerstone in emergency cardiovascular pharmacotherapy. Used primarily as a potent vasopressor in treating septic shock and other hypotensive states, its market trajectory is shaped by evolving clinical practices, manufacturing capacities, regulatory developments, and broader healthcare trends. This comprehensive analysis explores the key market dynamics influencing Norepinephrine Bitartrate's financial landscape, providing actionable insights for stakeholders.

Global Market Overview

The global demand for norepinephrine is driven predominantly by critical care requirements. The Global Market Insights report estimates the vasopressor market size to surpass USD 3 billion by 2027, with norepinephrine accounting for approximately 70% of usage in vasopressor therapy. The increasing prevalence of sepsis—with the World Health Organization estimating approximately 49 million cases annually—has cemented norepinephrine's status as the first-line agent in septic shock management.

Regionally, North America commands the largest market share, attributed to advanced healthcare infrastructure, high sepsis incidence, and high adoption rates of evidence-based protocols. Europe follows, benefiting from robust critical care practices. The Asia-Pacific region exhibits rapid growth due to expanding healthcare access, rising critical illness burden, and increasing pharmaceutical manufacturing capacities.

Market Drivers

Clinical Preference and Evidence-Based Guidelines

Norepinephrine is recommended as the initial vasopressor of choice in septic shock by the Surviving Sepsis Campaign and other clinical guidelines, reinforcing steady demand. The drug's rapid onset, potent vasoconstrictive effect, and favorable safety profile sustain its frontline status, thereby bolstering its market stability.

Regulatory Approvals and Expansion

Regulatory authorities, including the FDA and EMA, continually approve new formulations, indications, and manufacturing facilities, broadening market access. Companies investing in stable, cost-effective manufacturing facilities in emerging markets aim to tap into underserved regions.

Expanding Critical Care Infrastructure

An increase in ICU beds, advanced monitoring, and training initiatives enhances capability to administer vasopressors. The surge in hospitalizations linked to critical illnesses sustains demand, especially amid aging populations and rising chronic disease burden.

Manufacturing and Supply Chain Dynamics

A concentrated manufacturer base—dominated by key players like Pfizer, Boehringer Ingelheim, and Hikma Pharmaceuticals—controls supply. Recent supply chain disruptions caused by geopolitical tensions and raw material scarcity have temporarily impacted availability but also incentivized diversification and local manufacturing initiatives.

Market Challenges

Synthetic and Biosimilar Competition

While norepinephrine remains proprietary to established manufacturers, biosimilar development is gaining momentum, offering potentially lower-cost alternatives and intensifying price competition.

Regulatory Hurdles

Stringent quality standards, especially for injectable products, increase manufacturing costs and compliance barriers. Variations in regulatory pathways across regions can delay market entry.

COVID-19 Pandemic Impact

The pandemic led to unpredictable fluctuations in critical care utilization. Initially, heightened demand led to shortages, but subsequent resource reallocation affected other areas of care, influencing overall market stability.

Costs and Reimbursement Policies

Pricing pressures from healthcare payers, especially in price-sensitive markets, influence procurement decisions. Reimbursement policies favoring cost-effectiveness can impact profit margins.

Financial Trajectory and Forecasts

Historical Performance

In the past decade, the market for norepinephrine experienced a compounded annual growth rate (CAGR) of approximately 5-6%. Growth driven by rising critical care needs, drug approval pipelines, and strategic manufacturing expansions. Sales revenues for leading manufacturers have reached into hundreds of millions USD globally.

Projected Trends (2023-2030)

Forecasts indicate a CAGR of 4-6%, with the global market potentially exceeding USD 4.5 billion by 2030. The analysis points to several key factors shaping this trajectory:

• Increased critical illness management: Aging populations and rising sepsis cases will sustain demand.
• Emerging markets: Expansion into Asia-Pacific and Latin America presents high-growth opportunities.
• Product innovation: Development of ready-to-use, stable formulations reduces preparation errors and enhances safety, driving adoption.
• Biosimilar entry: Price competition and increased accessibility are expected to alter the market landscape, potentially compressing profit margins but expanding access.

Revenue Growth and Pricing Strategies

Major manufacturers are adopting strategic pricing models to balance profitability with accessibility. Volume-based discounts, bundled procurement, and partnerships with government procurement agencies are prevalent.

Regulatory and Patent Landscape

Patent expirations in the coming years could enable biosimilar entry, fostering competition. Regulatory agencies continue to refine approval pathways for generic and biosimilar versions to ensure quality and safety, influencing market entries and longevity.

Market Entry and Investment Opportunities

Emerging biosimilar manufacturers and local producers in developing economies represent strategic investment targets. Innovators focusing on stable, simplified formulations can capitalize on safety and supply chain resilience trends.

Impact of Technological and Clinical Developments

Advances in infusion pump technology, real-time blood pressure monitoring, and personalized medicine Informatics can optimize norepinephrine use, increase efficacy, and reduce adverse effects, further supporting demand.

Key Market Players

• Pfizer Inc. – Dominant in the global market, with extensive manufacturing and distribution networks.
• Boehringer Ingelheim – Focused on critical care formulations and biosimilar development.
• Hikma Pharmaceuticals – Regional leader emphasizing affordable, high-quality injectables.
• Hospira (Part of Pfizer) – Pioneer in sterile injectables and biosimilars.

Market consolidation trends favor collaborations, licensing agreements, and acquisitions, shaping competitive dynamics.

Conclusion

The financial outlook for norepinephrine bitartrate in 0.9% sodium chloride is resilient, underpinned by its critical role in life-saving therapy and evolving healthcare infrastructure. While facing challenges from regulatory complexities, biosimilar competition, and geopolitical factors, strategic innovation, expanding critical care capabilities, and entry into emerging markets present substantial growth opportunities. Providers and investors should monitor regulatory developments and technological innovations to navigate the evolving landscape effectively.

---

Key Takeaways

• Norepinephrine remains the primary vasopressor in critical care, ensuring ongoing stable demand.
• Market growth is projected at a 4-6% CAGR through 2030, driven by emerging markets and clinical guideline adherence.
• Supply chain resilience and biosimilar competition are vital factors influencing pricing and profitability.
• Technological innovations and pipeline formulations will further refine treatment efficacy and safety.
• Strategic investments in manufacturing capacity in emerging regions can capitalize on unmet demand and cost advantages.

---

FAQs

1. What factors are most influencing the future demand for norepinephrine?
The primary drivers include the rising incidence of sepsis globally, expanding ICU infrastructure, clinical guideline adherence favoring norepinephrine, and technological advancements ensuring safer administration.

2. How will biosimilar competition impact the market?
Biosimilars are likely to offer lower-cost alternatives, increasing accessibility and pressuring existing manufacturers to optimize pricing strategies, potentially affecting profit margins but expanding overall aggregate demand.

3. Are there regulatory risks affecting norepinephrine formulations?
Yes. Stringent quality and safety standards, especially for injectable drugs, can delay approvals and increase manufacturing costs, influencing market entry and profitability.

4. What opportunities exist for investors within this market?
Investors can explore biosimilar manufacturing, regional production facilities in emerging markets, and formulations with improved stability and safety profiles.

5. How can technological innovations shape the market's trajectory?
Advancements in infusion devices, monitoring, and personalized medicine will enhance safety, efficacy, and ease of use, further solidifying norepinephrine’s role and expanding its market.

---

Sources:
[1] Global Market Insights, "Vasopressor Market Size & Forecast," 2022.
[2] WHO Report, "Sepsis Incidence and Management," 2021.
[3] Surviving Sepsis Campaign Guidelines, 2020.